1-[[1-(4-ethylphenyl)sulfonyl-4,4-difluoropyrrolidin-2-yl]methyl]-N-methyltriazole-4-carboxamide
C17H21F2N5O3S — CID 171144322
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[[1-(4-ethylphenyl)sulfonyl-4,4-difluoropyrrolidin-2-yl]methyl]-N-methyltriazole-4-carboxamide
1-[[1-(4-ethylphenyl)sulfonyl-4,4-difluoropyrrolidin-2-yl]methyl]-N-methyltriazole-4-carboxamide (PubChem CID 171144322) has the molecular formula C17H21F2N5O3S and a molecular weight of 413.45 g/mol. Its IUPAC name is 1-[[1-(4-ethylphenyl)sulfonyl-4,4-difluoropyrrolidin-2-yl]methyl]-N-methyltriazole-4-carboxamide.
Molecular Properties
| Compound Name | 1-[[1-(4-ethylphenyl)sulfonyl-4,4-difluoropyrrolidin-2-yl]methyl]-N-methyltriazole-4-carboxamide |
|---|---|
| PubChem CID | 171144322 |
| Molecular Formula | C17H21F2N5O3S |
| Molecular Weight | 413.45 g/mol |
| Exact Mass | 413.13 |
| IUPAC Name | 1-[[1-(4-ethylphenyl)sulfonyl-4,4-difluoropyrrolidin-2-yl]methyl]-N-methyltriazole-4-carboxamide |
| SMILES | CCc1ccc(S(=O)(=O)N2CC(F)(F)CC2Cn2cc(C(=O)NC)nn2)cc1 |
| InChI | InChI=1S/C17H21F2N5O3S/c1-3-12-4-6-14(7-5-12)28(26,27)24-11-17(18,19)8-13(24)9-23-10-15(21-22-23)16(25)20-2/h4-7,10,13H,3,8-9,11H2,1-2H3,(H,20,25) |
| InChIKey | VXEAESVPPDJXOK-UHFFFAOYSA-N |
| XLogP | 1.30 |
| TPSA | 97.19 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 413.45 |
| LogP ≤ 5 | 1.30 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 171144322 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.